European Leukemia Trial Registry
Trial: LENAMAINT

More Details
Title Lenalidomide Maintenance Therapy in Patients With MDS or AML
Scientific Title Lenalidomide Maintenance Therapy in Patients With MDS or AML With Cytogenetic Abnormalities Involving Monosomy 5 or del5q After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Short Title LENAMAINT
Trialgroup Deutsche MDS
Type of Trial multicentric, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status Closed
Start of Recruitment 01.01.2009
Leader Platzbecker, Prof. Dr. med., Uwe
Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Diagnostics

gene expression
Hämatologisches Labor, Universitätsklinikum Dresden

Remark - MDS IPSS INT-2/HIGH und AML in CR - Del5q - in CR after Tx
created 07.01.2010 Irene Gleske
changed 20.03.2015 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org